União Química
Date: Feb 2015
Client: União Química
Counterparty: Novartis
Industry: Healthcare
Amount: Undisclosed amount
Transaction:
Landmark Alantra acted as exclusive financial advisor of União Química Farmacêutica Nacional, one of Brazil´s biggest pharmaceutical companies, in the acquisition of a manufacturing site from Novartis, one of world´s biggest pharmaceuticals. This plant manufactures medicines to supply the Latin American market.
Besides the acquisition of the asset, the transaction also included a long term manufacturing agreement of Novartis medicines by União Química.
Feb 2015
![](https://landmark-cap.com/hs-fs/hubfs/Banderas%20Pa%C3%ADses/bandera_suiza.png?width=27&height=18&name=bandera_suiza.png)
Financial advisor to
![](https://landmark-cap.com/hs-fs/hubfs/Logos%20Transacciones/uniao%20quimica.jpg?width=130&height=48&name=uniao%20quimica.jpg)
on the acquisition of the Taboao da Serra/SP plant from
![](https://landmark-cap.com/hs-fs/hubfs/Logos%20Transacciones/novartis.png?width=130&height=48&name=novartis.png)
Undisclosed amount
Similar transactions
Nov 2021
![](https://landmark-cap.com/hs-fs/hubfs/Banderas%20Pa%C3%ADses/bandera_francia.jpg?width=27&height=18&name=bandera_francia.jpg)
Financial advisor to
![](https://landmark-cap.com/hs-fs/hubfs/Logos%20Transacciones/centrovet.png?width=130&height=48&name=centrovet.png)
on the sale of 34% of the shares to
![](https://landmark-cap.com/hs-fs/hubfs/Logos%20Transacciones/virbac.jpg?width=130&height=48&name=virbac.jpg)
With this transaction, Virbac completes the acquisition of 100% of the company since the initial purchase in 2012
Leer más